shutterstock_1635580639_sundry_photography

Sundry Photography / Shutterstock.com

28 August 2020Big PharmaRory O'Neill

Genentech to face revived Hemlibra claims

Genentech and Chugai Pharmaceutical will have to face claims that its haemophilia drug Hemlibra (emicizumab-kxwh) infringed a patent owned by Takeda subsidiary Baxalta.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Genentech seeks ‘tens of millions in unpaid royalties’ in licence dispute

7 March 2023 The Roche subsidiary says the licensee owes payments on “stockpile” of MS drug Tysabri.

Genentech prevails in Baxalta haemophilia treatment suit

17 January 2022 Genentech has gained a win in a suit claiming that its haemophilia treatment Hemlibra infringes a patent owned by Takeda subsidiary, Baxalta, after a US federal judge held that parts of the patent were invalid.

Taiwanese biotech built on ‘foundation of lies’, says DoJ

8 July 2021 US prosecutors have charged the founders of Taiwanese biosimilar manufacturer JHL Biotech with stealing Genentech trade secrets.

More on this story

Genentech seeks ‘tens of millions in unpaid royalties’ in licence dispute

7 March 2023 The Roche subsidiary says the licensee owes payments on “stockpile” of MS drug Tysabri.

Genentech prevails in Baxalta haemophilia treatment suit

17 January 2022 Genentech has gained a win in a suit claiming that its haemophilia treatment Hemlibra infringes a patent owned by Takeda subsidiary, Baxalta, after a US federal judge held that parts of the patent were invalid.

Taiwanese biotech built on ‘foundation of lies’, says DoJ

8 July 2021 US prosecutors have charged the founders of Taiwanese biosimilar manufacturer JHL Biotech with stealing Genentech trade secrets.

More on this story

Genentech seeks ‘tens of millions in unpaid royalties’ in licence dispute

7 March 2023 The Roche subsidiary says the licensee owes payments on “stockpile” of MS drug Tysabri.

Genentech prevails in Baxalta haemophilia treatment suit

17 January 2022 Genentech has gained a win in a suit claiming that its haemophilia treatment Hemlibra infringes a patent owned by Takeda subsidiary, Baxalta, after a US federal judge held that parts of the patent were invalid.

Taiwanese biotech built on ‘foundation of lies’, says DoJ

8 July 2021 US prosecutors have charged the founders of Taiwanese biosimilar manufacturer JHL Biotech with stealing Genentech trade secrets.

More features

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB